GO39942 (Polarix)

Trial description
A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Contact name
Dr George Follows
Trial start date
Friday, November 16, 2018
Trial end date
Wednesday, October 30, 2019
Trial tumour type
Show on Radiotherapy